Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 23, 2016

Primary Completion Date

March 1, 2017

Study Completion Date

March 1, 2017

Conditions
DiabetesWound InfectionHealthy Volunteers
Interventions
DRUG

Tedizolid

PROCEDURE

Microdialysis Catheter Insertion

A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.

Trial Locations (1)

06102

Hartford Hospital, Hartford

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Hartford Hospital

OTHER

NCT02620787 - Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis | Biotech Hunter | Biotech Hunter